Payment overview · 2025
General Payments
$2,247.74
107 reported records · 27 companies
Healthcare provider profile · identity verified
Harjeet Narula, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSBORO, TN · NPI 1811928799
Verified facts
What the public records show
CMS Open Payments records show Harjeet Narula, M.D. received $2,247.74 in general payments during 2025 across 107 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 672 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $376.36 | 16.7% | 11 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $356.56 | 15.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $229.82 | 10.2% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $168.78 | 7.5% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $130.28 | 5.8% | 8 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $103.71 | 4.6% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.17 | 4.0% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $81.26 | 3.6% | 5 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.16 | 3.5% | 5 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $77.41 | 3.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.26 | 2.9% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $64.07 | 2.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.53 | 2.7% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $59.59 | 2.6% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$55.46 | 2.5% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $33.47 | 1.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.93 | 1.5% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.22 | 1.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.50 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.80 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.22 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.15 | 0.8% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $16.88 | 0.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.46 | 0.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.42 | 0.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.76 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.51 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,247.74 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $356.56 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $311.11 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $250.04 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $249.25 | 3 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $240.20 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $232.83 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $229.82 | 15 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $130.28 | 8 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $103.71 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $90.17 | 12 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $77.41 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.26 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $61.53 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $60.00 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $59.59 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $55.46 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $50.49 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $33.47 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $28.67 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $28.22 | 2 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 672 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
672 | 69 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 924 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 847 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 110 |
| Eliquis | Apixaban | 672 | 69 |
| Potassium Chloride | Potassium Chloride | 546 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 490 | 63 |
| Furosemide | Furosemide | 480 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 435 | 71 |
| Sertraline Hcl | Sertraline Hcl | 410 | 32 |
| Gabapentin | Gabapentin | 382 | 77 |
| Lisinopril | Lisinopril | 380 | 100 |
| Mirtazapine | Mirtazapine | 313 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 303 | 49 |
| Divalproex Sodium | Divalproex Sodium | 299 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 294 | 56 |
| Buspirone Hcl | Buspirone Hcl | 261 | 41 |
| Omeprazole | Omeprazole | 250 | 67 |
| Fluoxetine Hcl | Fluoxetine Hcl | 226 | 15 |
| Trazodone Hcl | Trazodone Hcl | 205 | 37 |
| Losartan Potassium | Losartan Potassium | 202 | 39 |
| Carvedilol | Carvedilol | 196 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 196 | 22 |
| Metformin Hcl | Metformin Hcl | 192 | 54 |
| Bumetanide | Bumetanide | 179 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 29 |
| Levofloxacin | Levofloxacin | 169 | 130 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 48 |
| Prednisone | Prednisone | 164 | 83 |
| Finasteride | Finasteride | 155 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 140 | 26 |
| Baclofen | Baclofen | 139 | suppressed |
| Sucralfate | Sucralfate | 132 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 130 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 122 | 94 |
| Clonazepam | Clonazepam | 121 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 26 |
| Levetiracetam | Levetiracetam | 118 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 55 |
| Montelukast Sodium | Montelukast Sodium | 116 | 25 |
| Spironolactone | Spironolactone | 111 | 25 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 110 | suppressed |
| Lorazepam | Lorazepam | 110 | 32 |
| Donepezil Hcl | Donepezil Hcl | 109 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 106 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 17 |
| Clonidine Hcl | Clonidine Hcl | 98 | 23 |
| Famotidine | Famotidine | 97 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 90 | suppressed |
| Memantine Hcl | Memantine Hcl | 90 | 11 |
| Alprazolam | Alprazolam | 87 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 43 |
| Promethazine Hcl | Promethazine Hcl | 86 | 26 |
| Lactulose | Lactulose | 83 | 14 |
| Cefdinir | Cefdinir | 82 | 73 |
| Dutasteride | Dutasteride | 82 | suppressed |
| Ranolazine Er | Ranolazine | 79 | suppressed |
| Meloxicam | Meloxicam | 78 | 33 |
| Sodium Chloride | 0.9 % Sodium Chloride | 78 | 13 |
| Allopurinol | Allopurinol | 72 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 22 |
| Cephalexin | Cephalexin | 68 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 22 |
| Insulin Lispro | Insulin Lispro | 66 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 65 | 36 |
| Solifenacin Succinate | Solifenacin Succinate | 63 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | suppressed |
| Olanzapine | Olanzapine | 59 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 59 | suppressed |
| Budesonide | Budesonide | 55 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 54 | suppressed |
| Linzess | Linaclotide | 54 | 12 |
| Primidone | Primidone | 54 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 25 |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 19 |
| Sevelamer Carbonate | Sevelamer Carbonate | 53 | suppressed |
| Risperidone | Risperidone | 52 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 17 |
| Amantadine | Amantadine Hcl | 49 | suppressed |
| Meropenem | Meropenem | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Fluconazole | Fluconazole | 46 | 28 |
| Azithromycin | Azithromycin | 45 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Jardiance | Empagliflozin | 40 | 12 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 12 |
| Nystatin | Nystatin | 38 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 34 |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 36 | 17 |
| Entacapone | Entacapone | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 14 |
| Atenolol | Atenolol | 35 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 33 | 13 |
| Flecainide Acetate | Flecainide Acetate | 32 | suppressed |
| Folic Acid | Folic Acid | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Roflumilast | Roflumilast | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Naproxen | Naproxen | 29 | 11 |
| Ozempic | Semaglutide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | 15 |
| Ertapenem | Ertapenem Sodium | 26 | 19 |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | 13 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 19 |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | 11 |
| Lidocaine Hcl | Lidocaine Hcl | 22 | 17 |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 14 |
| Mupirocin | Mupirocin | 21 | 15 |
| Nyamyc | Nystatin | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 16 |
| Metolazone | Metolazone | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | 11 |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Daptomycin-0.9% Nacl | Daptomycin In 0.9 % Sod Chlor | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,247.74 · 107 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, BodyGuardian, CAPLYTA, CeQur Simplicity, Dexcom G6 Transmitter, ELIQUIS, ENHERTU, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JOURNAVX, Kerendia, Korlym, MINIMED 780G, Ohtuvayre, Ozempic, RECORLEV, REXULTI, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, TWIIST, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, ZENPEP, ZTLido | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error